We are delighted to announce that we have been selected for both a poster and short talk presentation at the CIMT 2024 annual meeting!
The short talk has been made by Sebastien Michel May 16th in...
We are delighted to announce that our abstract on the preliminary clinical results of the therapeutic cancer vaccine PDC*lung01 in patients (pts) with stage IV NSCLC was accepted for an oral...
PDC*line Pharma will be presenting a poster in the “Therapeutic Vaccination” session of the 20th Cancer IMmunoTherapy (CIMT) annual meeting taking place from 3 to 5 May 2023, in Mainz (Germany). The...
We are delighted to announce that our CEO will be presenting at the 6th Europe Neoantigen Summit 2023 hosted by Hanson Wade in Amsterdam (Netherlands) from April 24-26th! He will be presenting PDC...
We are delighted to announce that our CEO will be presenting at the Neoantigen-Based Therapies Summit 2022 hosted by Hanson Wade in Boston from October 24-26th! He will be presenting PDC*line Pharma...
We are very pleased to announce that our abstract describing our current phase I/II clinical trial objectives and design with our cancer vaccine PDC*lung01 has been accepted for presentation at the...
Eric Halioua, our CEO, will give a company presentation and be part of the Advances in Immuno-Oncology Panel at the SACHS FORUM 14th Annual European Life Sciences CEO Forum. He will also give a...
PDC*line Pharma team wishes you and your loved ones a festive & healthy holiday season and a successful 2021!
Our President & CEO Eric Halioua will make a company presentation at the Belgium-Korea Pharma-Bio Partnering on the 13th November 2019 in Brussels. This seminar organized by Korea Trade-Investment...
